GSK has reported 2025 revenue of GBP 32.7 billion (approximately USD 43.2 billion), a 7% increase at constant exchange rates. The company's growth was driven primarily by its specialty medicines segment, which grew 17% to GBP 13.5 billion (USD 17.8 billion). Within this segment, the HIV franchise delivered sales of GBP 7.7 billion (USD 10.2 billion), while the oncology business saw rapid growth of 43% to GBP 2.0 billion (USD 2.6 billion), bolstered by strong performance of PD-1 inhibitor Jemperli.

The vaccines business grew 2% to GBP 9.2 billion (USD 12.1 billion), with shingles vaccine Shingrix remaining the company's top-selling product at GBP 3.6 billion (USD 4.7 billion). The general medicines segment revenue was stable at GBP 10.0 billion (USD 13.3 billion), with the triple therapy Trelegy Ellipta for asthma and COPD performing well. GSK secured five new product or indication approvals from US regulators in 2025 and forecasts 2026 revenue growth of 3% to 5%, with a longer-term ambition to exceed GBP 40.0 billion in sales by 2031.

PharmCube's NextBiopharm® database shows that, while GSK focuses on vaccines, the company develops other therapies such as antibody-based treatments, drug conjugates, and gene therapies. Click here to request a free trial for NextBiopharm®.